Effect of extended duration of thromboprophylaxis for medically ill patients

被引:2
|
作者
Wang, Xing [1 ]
Chen, Yuqi [1 ]
Wen, Dingke [1 ]
You, Chao [1 ,2 ]
Ma, Lu [1 ]
机构
[1] Sichuan Univ, West China Hosp, Dept Neurosurg, 37 Guo Xue Xiang, Chengdu 610041, Sichuan, Peoples R China
[2] Sichuan Univ, West China Brain Res Ctr, 37 Guo Xue Xiang, Chengdu 610041, Sichuan, Peoples R China
关键词
Venous thromboembolism; Thromboprophylaxis; Acute disease; Low molecular weight heparin; Direct oral anticoagulant; Stroke; VENOUS THROMBOEMBOLISM; RISK; PROPHYLAXIS; ENOXAPARIN; EVENTS;
D O I
10.1016/j.ejim.2023.03.032
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: There are knowledge gaps regarding the comparative efficacy and safety of various venous thromboprophylaxis regimens with extended timing in patients hospitalized for acute medical illnesses. This study aims to investigate the optimal regimen for the prevention of venous thromboembolism in these patients. Methods: We conducted a Bayesian network meta-analysis of randomized controlled trials (RCTs) comparing different venous thromboprophylaxis regimens for acutely ill medical patients. Outcomes included venous thromboembolism, major bleeding, and all-cause mortality. Risk ratios (RR) and associated 95% credible interval (CrI) were estimated. In addition, we assessed the most effective interventions in a subgroup of patients with stroke. Results: We identified five RCTs involving 40,124 patients. Extended thromboprophylaxis with direct oral anticoagulant (DOAC) (RR 0.78, 95% CrI 0.68 to 0.89) and low molecular weight heparin (LMWH) (RR 0.62, 95% CrI 0.45 to 0.84) were superior to standard therapy in the prevention of venous thromboembolism. However, both of them (DOAC: RR 1.99, 95% CrI 1.38 to 2.92; LMWH: RR 2.56, 95% CrI 1.26 to 5.68) lead to a significant increase in major bleeding). Moreover, both LMWH (RR 0.76, 95% CrI 0.57 to 1.00) and DOAC (RR 0.86, 95% CrI 0.76 to 0.98) with extended thromboprophylaxis showed favorable net clinical benefit compared to standard therapy. Conclusions: Extended thromboprophylaxis, especially with LMWH, showed better efficacy in venous thromboembolism reduction with increased risk of major bleeding. The beneficial effect of LMWH with extended timing has also been shown in stroke patients. Overall, extended thromboprophylaxis is associated with a positive net clinical benefit.
引用
收藏
页码:22 / 30
页数:9
相关论文
共 50 条
  • [41] THROMBOPROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN ACUTE MEDICALLY ILL PATIENTS: A NETWORK META-ANALYSIS
    Goswami, H.
    Alsumali, A.
    Chakankar, S.
    Farag, H.
    Eguale, T.
    VALUE IN HEALTH, 2019, 22 : S118 - S118
  • [42] DIRECT ORAL ANTICOAGULANTS FOR EXTENDED THROMBOPROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS
    Lateef, Noman
    Khan, Muhammad Shahzeb
    Khan, Safi U.
    Ranka, Sagar
    Mannan, Abdul
    Kaluski, Edo
    Alla, Venkata M.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 2109 - 2109
  • [43] Extended vs. standard-duration thromboprophylaxis in acutely ill medical patients: A systematic review and meta-analysis
    Chiasakul, Thita
    Evans, Christina R.
    Spyropoulos, Alex C.
    Raskob, Gary
    Crowther, Mark
    Cuker, Adam
    THROMBOSIS RESEARCH, 2019, 184 : 58 - 61
  • [44] The risk of stroke among acutely ill hospitalized medical patients: lessons from recent trials on extended-duration thromboprophylaxis
    Marszalek, Jolanta
    Mehrsefat, Sara
    Chi, Gerald
    EXPERT REVIEW OF HEMATOLOGY, 2017, 10 (08) : 679 - 684
  • [45] Efficacy and safety of extended antithrombotic prophylaxis in elderly medically ill patients
    Dentali, Francesco
    Mumoli, Nicola
    Fontanella, Andrea
    Di Minno, Matteo Nicola Dario
    EUROPEAN RESPIRATORY JOURNAL, 2017, 49 (01)
  • [46] EXTENDED THROMBOPROPHYLAXIS WITH BETRIXABAN IS COST-EFFECTIVE IN ACUTELY ILL MEDICAL PATIENTS
    Huang, W.
    Anderson, F.
    Bucior, I
    Neuman, W. R.
    Cohen, A. T.
    VALUE IN HEALTH, 2018, 21 : S61 - S61
  • [47] Efficacy and safety of direct oral anticoagulants for standard duration thromboprophylaxis in hospitalized medically-ill patients: meta-analysis of randomized controlled trials
    Al Yami, Majed
    Alfayez, Osamah
    Alsheikh, Razan
    PHARMACOTHERAPY, 2017, 37 (12): : E233 - E234
  • [48] EXTENDED DURATION BETRIXABAN REDUCES THE RISK OF VENOUS THROMBOEMBOLISM VERSUS STANDARD DURATION ENOXAPARIN IN THE POST PARENTERAL PERIOD AMONG HOSPITALIZED MEDICALLY ILL PATIENTS
    Gibson, C. Michael
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 1859 - 1859
  • [49] Impact of age on the efficacy and safety of extended-duration thromboprophylaxis in medical patients
    Yusen, Roger D.
    Hull, Russell D.
    Schellong, Sebastian M.
    Tapson, Victor F.
    Monreal, Manuel
    Samama, Meyer-Michel
    Chen, Min
    Deslandes, Bruno
    Turpie, Alexander G. G.
    THROMBOSIS AND HAEMOSTASIS, 2013, 110 (06) : 1152 - 1163
  • [50] Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically III Patients in the MAGELLAN and MARINER Trials
    Spyropoulos, Alex C.
    Raskob, Gary E.
    Cohen, Alexander T.
    Ageno, Walter
    Weitz, Jeffrey, I
    Spiro, Theodore E.
    Lu, Wentao
    Lipardi, Concetta
    Albers, Gregory W.
    Elliott, C. Gregory
    Halperin, Jonathan L.
    Hiatt, William R.
    Maynard, Gregory
    Steg, P. Gabriel
    Sugarmann, Chiara
    Barnathan, Elliot S.
    CIRCULATION, 2022, 145 (19) : 1471 - 1479